Curriculum Vitae
Kyle J. Smith, MD, FACC
1783 Troup Hwy, Tyler, Texas 75701

Office (903)-595-2283 Fax (903)-597-2238

Practice

2009-Present	Tyler Cardiac and Endovascular Center - 1769 Troup Hwy, Tyler, TX
2009-Present	Cardiovascular Associates of East Texas, P.A.

Affiliation

2009-Present	CAET - Research - 1761 Troup Hwy, Tyler, Texas
1/1/13-4/26/13	TAD Clinical Research - 1741 Troup Hwy, Tyler, Texas

Education

7/1998-5/2002	University of Texas School of Medicine at San Antonio San Antonio, Texas Doctor of Medicine
8/1993-5/1997	University of Texas at Austin Austin, Texas Bachelor of Science (Major: Biology-High Honors)

Post-Graduate Education

7/2008-6/2009	Texas A&M University Health Science Center/Scott & White Hospital, Interventional Cardiology Fellowship
7/2005-6/2008	Texas A&M University Health Science Center/Scott & White Hospital Cardiovascular Disease Fellowship
6/2002-6/2005	Wake Forest University Baptist Medical Center Internal Medicine Residency and Internship

Board Certification

2009	American Board of Internal Medicine, Interventional Cardiology
2008	American Board of Internal Medicine, Cardiovascular disease
2008	Nuclear Cardiology Board Certification
2005	American Board of Internal Medicine, Internal Medicine

Licensure

2005	State of Texas

Hospital Appointments

CHRISTUS Trinity Mother Frances Hospital, Tyler, Texas

CHRISTUS Trinity Mother Frances Hospital, Jacksonville, Texas

UT Health East Texas (ETMC), Tyler, Texas

UT Health East Texas (ETMC), Athens, Texas

UT Health East Texas (ETMC), Quitman, Texas

UT Health East Texas (ETMC), Pittsburg, Texas

Baylor Scott & White Texas Spine and Joint Hospital, Tyler, Texas

Titus Regional Medical Center, Mt. Pleasant, Texas

Research

Co-Investigator - FORXIGA-HF - Study to Evaluate the Effect of Dapagliflozin on the Incidence of Worsening Heart Failure or Cardiovascular Death in Patients with Chronic Heart Failure with Reduced Ejection Fraction. (D1699C00001)

Co-Investigator - PROVE-HF - A 52 Week, open label evaluation on the effects of sacubitril/valsartan (LCZ696) therapy on biomarkers, myocardial remodeling and patient-reported outcomes in heart failure with reduced left ventricular ejection fraction.

Co-Investigator - RANGER II SFA - A 3:1 Randomized Trial Comparing the Boston Scientific RANGER™ Paclitaxel Coated Balloon vs Standard Balloon Angioplasty for the Treatment of Superficial Femoral Arteries (SFA) and Proximal Popliteal Arteries (PPA)

Co-Investigator - REVEAL - Revolution™ Peripheral Atherectomy System for Lower Extremity Peripheral Arterial Revascularization. (The REVEAL Study)

Co-Investigator - TOBA II BTK - Tack Optimized Balloon Angioplasty Study for the Below The Knee Arteries Using the Tack Endovascular System® (TOBA II BTK)

Co-Investigator – COPPER A – "The Occlusion Perfusion Catheter for Optimal Delivery of Paclitaxel for the Prevention of Endovascular Restenosis – Above the Knee"

Co-Investigator - VOYAGER-PAD – An international, multicenter randomized, double-blind, placebo controlled phase 3 trial investigating the efficacy and safety of rivaroxaban to reduce the risk of major thrombotic vascular events in patients with symptomatic peripheral artery disease undergoing lower extremity revascularization procedures.

Co-Investigator - CHAMP-HF – Observational Registry of Treatment Patterns in U.S. Heart Failure Patients with Reduced Ejection Fraction.

Co-Investigator – ABLATE. The trial is a prospective, multi-center, non-randomized registry evaluating the safety and effectiveness of Excimer Laser Atherectomy (ELA) using the Spectranetics Turbo-Elite Laser Ablation Catheter.

Co-Investigator – MIMICS-2. Evaluation of Safety and Efficacy of the BioMimics 3DTM Stent System in the Femoropopliteal Arteries of Patients with Symptomatic Peripheral Arterial Disease.

Co-Investigator - DECLARE - A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Effect of Dapagliflozin 10mg Once Daily on the Incidence of Cardiovascular Death, Myocardial Infarction or Ischemic Stroke in Patients with Type 2 Diabetes.

Co-Investigator - ABSORB III - Randomized Controlled Trial. A Clinical Evaluation of Absorb™ BVS, the Everolimus Eluting Bioresorbable Vascular Scaffold in the treatment of Subjects with de novo Native coronary Artery Lesions.

Co-Investigator - AD HOC PCI - A randomized, open-label, multiple-center, parallel group, study to compare the platelet inhibition with Verify Now™ assay of ticagrelor vs. clopidogrel in troponin negative Acute Coronary Syndrome (ACS) subjects undergoing Ad Hoc percutaneous coronary intervention (PCI)

Co-Investigator - EXCITE - Excimer laser randomized Controlled study for treatment of femoropopliteal In-Stent Restenosis.

Co-Investigator - EUCLID -A randomized, double-blind, parallel group, multicenter phase IIIb study to compare ticagrelor with clopidogrel treatment on the risk of cardiovascular death, myocardial infarction and ischemic stroke in patients with established Peripheral Artery Disease (EUCLID – Examining Use of tiCagreLor In paD)

Co-Investigator – PARADIGM - A multicenter, randomized, double-blind, parallel group, active-controlled study to evaluate the efficacy and safety of LCZ696 compared to enalapril on morbidity and mortality in patients with chronic heart failure and reduced ejection fraction.

Primary Investigator - TAO: "A randomized, double-blind, triple-dummy trial to compare the efficacy of otamixaban with Unfractionated Heparin + eptifibatide, in patients with Unstable angina/Non ST segment Elevation Myocardial infarction scheduled to undergo an early invasive strategy"

Co-Investigator - Taxus Libertē "A prospective, multi-center study designed to observe clinical outcomes in patient receiving the TAXUS Libertē-Paclitaxel-Eluting Coronary Stent and prasugrel as part of a dual antiplatelet therapy drug regimen"

Co-Investigator – RESOLUTE – A Clinical Evaluation of the Medtronic Endeavor® Resolute Zotarolimus-Eluting Coronary Stent System in the Treatment of *De Novo* Lesions in Native Coronary Arteries with a Reference Vessel Diameter of 2.25 mm to 4.2 mm.

Co-Investigator – ENDEAVOR SVS – A Clinical Evaluation of the Medtronic Endeavor Zotarolimus-Eluting Coronary Stent System in the Treatment of *De novo* Lesions in Small Diameter Native Coronary Arteries.

Principal Investigator – The Complete® SE SFA Study: The Medtronic Complete Self-Expanding(SE) SFA Stent for the Treatment of Atherosclerotic Lesions in the Superficial Femoral Artery and/or Proximal Popliteal Artery

Co-Investigator - VISTA-16 Evaluation of the Safety and Efficacy of Short-term A-002 Treatment in Subjects with Acute Coronary Syndromes.